Table 2 Remission rate after infliximab induction therapy
Indication of IFX therapy | Number and rate of remission | |
|---|---|---|
Overall | 167 (46%) | |
Therapy-refractory CD by localization | 45 (39.47%) | |
Ileum | 3/10 (30%) | |
Colon | 7/29 (24.13%) | |
Ileo-colonic | 29/46 (63.04%) | |
Ileo-colonic and other small bowel | 5/28 (17.85%) | |
Oesophagus | 1/1 | |
Therapy-refractory and fistulizing | 6 (37.5%) | |
Fistulizing | 95 (48.71%) | |
Perianal | 72/148 (48.64%) | |
Enterocutaneous | 7/24 (29.16%) | |
Enterovaginal | 3/11 | |
Other | 4/12 | |
Mixed | 6/7 | |
Steroid dependent | 15 (57.69%) | |
Ileum | 3/3 | |
Colon | 3/4 | |
Ileo-colic | 9/19 (47.36%) | |
Metastatic | 5 | Na. |
Other | 1 | Na. |